The combination of osimertinib and savolitinib improves survival in patients with EGFR-mutated NSCLC with MET alterations ...

Trastuzumab rezetecan significantly improves progression-free survival in HER2-low advanced breast cancer, regardless of ...

Darolutamide plus ADT and radiotherapy reduced the risk of metastasis or death by 58% compared with ADT and radiation alone.

The VOLGA trial showed that durvalumab plus EV improves EFS, OS, for patients with MIBC who don’t receive cisplatin-based ...

The early promise of therapeutic gold seen in clinical trials of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd; Enhertu) for HER2-low, hormone receptor (HR)-positive early-stage ...

Discover the key highlights and what to expect at ESMO 2026, including groundbreaking research and advancements in oncology.

Men with metastatic hormone-sensitive prostate cancer who received androgen receptor pathway inhibitor doublets had longer ...

The FDA granted traditional approval to pembrolizumab (Keytruda) or its subcutaneous formulation for patients with ...

On Oct. 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval for dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal cancer (LARC) that is ...

Daly ME, Simone CB II, Redman MW, et al. Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer ...

Chiaretti S, Piciocchi A, Skert C, et al. Ponatinib–blinatumomab or imatinib–chemotherapy for adult Ph-positive ALL. N Engl J Med. 2026;395:1483–94. A frontline chemotherapy-free regimen of ponatinib ...